Source:http://linkedlifedata.com/resource/pubmed/id/12665680
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2003-3-31
|
| pubmed:abstractText |
Vinorelbine and docetaxel are two effective drugs in esophageal cancer; our purpose was to evaluate efficacy and toxicity of a combination of these drugs in recurrent squamous cell esophageal cancer. Twenty patients previously treated with concomitant chemoradiotherapy (n = 14), surgery alone (n = 2), surgery plus radiotherapy (n = 2), or concomitant chemoradiotherapy + surgey (n = 2) were enrolled. Thirteen patients had a local-regional recurrence, two patients had metastases, and five patients had both. The doses were 80 mg/m(2) for docetaxel and 20 mg/m(2) for vinorelbine on d 1 every 21 d for a maximum of six cycles. Twenty patients received a total of 106 cycles (median per patient, 5). Neutropenia was the most frequent and severe side effect (grade 4 in 80%; grade 3 in 20%). The overall response rate was 60%, which included 3 of 20 complete responses (15%) and 9 of 20 partial responses (45%). Median response duration was 7 mo (2-50+). Overall median survival was 10.5 mo (range, 2-55+). A dysphagia improvement was observed in 81% of patients. In conclusion, the data from this phase II study indicate that this combination is effective in recurrent heavily pretreated patients with a short-lasting manageable toxicity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/Vinblastine,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/vinorelbine
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1357-0560
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
20
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
19-24
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:12665680-Adult,
pubmed-meshheading:12665680-Aged,
pubmed-meshheading:12665680-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:12665680-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12665680-Carcinoma, Squamous Cell,
pubmed-meshheading:12665680-Drug Administration Schedule,
pubmed-meshheading:12665680-Drug Synergism,
pubmed-meshheading:12665680-Esophageal Neoplasms,
pubmed-meshheading:12665680-Female,
pubmed-meshheading:12665680-Follow-Up Studies,
pubmed-meshheading:12665680-Humans,
pubmed-meshheading:12665680-Male,
pubmed-meshheading:12665680-Middle Aged,
pubmed-meshheading:12665680-Neoplasm Recurrence, Local,
pubmed-meshheading:12665680-Paclitaxel,
pubmed-meshheading:12665680-Taxoids,
pubmed-meshheading:12665680-Treatment Outcome,
pubmed-meshheading:12665680-Vinblastine
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma.
|
| pubmed:affiliation |
Medical Oncology Department, San Giovanni Antica Sede Hospital, Torino, Italy. mario.airoldi@jumpy.it
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|